https://scholars.lib.ntu.edu.tw/handle/123456789/549413
標題: | Persistently elevated soluble MHC class i polypeptide-related sequence A and transforming growth factor-β1 levels are poor prognostic factors in head and neck squamous cell carcinoma after definitive chemoradiotherapy | 作者: | JENNY LING-YU CHEN Chang C.-C. YU-SEN HUANG HUNG-YANG KUO Chen T.-Y. CHUN-WEI WANG SUNG-HSIN KUO Lin Y.-L. |
公開日期: | 2018 | 出版社: | Public Library of Science | 卷: | 13 | 期: | 8 | 來源出版物: | PLoS ONE | 摘要: | We evaluated the prognostic significance of immunologic inhibitory biomarkers in head and neck squamous cell carcinoma (HNSCC) patients undergoing definitive chemoradiotherapy (CRT). Thirty patients were prospectively enrolled. Plasma levels of soluble MHC class I polypeptide-related sequence A (sMICA) and transforming growth factor-β1 (TGF-β1) were measured before and 2 weeks after CRT. The median follow-up was 32.9 months (range: 12.4-40.6 months). The pre-treatment sMICA (p < 0.001) and TGF-β1 (p < 0.001) levels were significantly increased in HNSCC patients, compared to healthy controls. In HNSCC patients, the median pre-CRT and post-CRT sMICA levels were 43.1 pg/mL and 65.3 pg/ mL, respectively, while the median pre-CRT and post-CRT TGF-β1 levels were 57.7 ng/mL and 36.0 ng/mL, respectively. After CRT, 19 patients (63.3%) exhibited persistently elevated sMICA, six patients (20.0%) exhibited persistently elevated TGF-β1, and five patients (16.7%) exhibited persistently elevated sMICA and TGF-β1. Patients with persistently elevated sMICA and TGF-β1 after CRT experienced an earlier tumor progression (p = 0.030), and poor overall survival (p = 0.010). Our results suggest that HNSCC patients who exhibit persistently elevated sMICA and TGF-β1 levels after CRT are at higher risk of tumor progression or death. ? 2018 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85051666287&doi=10.1371%2fjournal.pone.0202224&partnerID=40&md5=9dfb9980a9cf26596eab1feef9dcb4af https://scholars.lib.ntu.edu.tw/handle/123456789/549413 |
ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0202224 | SDG/關鍵字: | cisplatin; major histocompatibility antigen class 1; soluble major histocompatibility complex class 1 polypeptide related sequence A; transforming growth factor beta1; unclassified drug; HLA antigen class 1; MHC class I-related chain A; TGFB1 protein, human; transforming growth factor beta1; tumor marker; adult; aged; Article; cancer prognosis; cancer staging; cancer survival; chemoradiotherapy; clinical article; clinical evaluation; controlled study; drug effect; female; follow up; head and neck squamous cell carcinoma; high risk patient; human; male; overall survival; protein blood level; radiation dose fractionation; tumor growth; blood; disease exacerbation; head and neck tumor; immunology; middle aged; prognosis; prospective study; solubility; Adult; Aged; Biomarkers, Tumor; Chemoradiotherapy; Disease Progression; Head and Neck Neoplasms; Histocompatibility Antigens Class I; Humans; Male; Middle Aged; Prognosis; Progression-Free Survival; Prospective Studies; Solubility; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor beta1 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。